drugset / Trial / NCT06089330
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer (mCRC).
Timeline
- Start
- 2024-01
- Primary completion
- 2024-07
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BECOTATUG | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Enlonstobart | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Comparator | Regorafenib | Small molecule | 160 mg | Oral |